Table 1 Summarized data of the included patients at diagnosis and at time of sRARP
From: Introduction of salvage prostatectomy in Denmark: the initial experience
Patient no. | Status at diagnosis | Status at sRARP | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
PSA (ng/mL) | Clinical stage | No. of positive cores | Gleason score | PSA (ng/mL) | Pathological stage | No. of positive cores | Estimated extension (%) | Gleason score | Surgical margins | Androgen deprivation | |
1 | 8.8 | cT3b | 12/12 | 3 + 4 | 2.2 | pT3a | 5/6 | 40 | 4 + 3 | Negative | Bicalutamide |
2 | 52.0 | cT3b | 10/11 | 4 + 5 | 3.8 | pT3b | 1/6 | 30 | 4 + 5 | Positive | Degarelix |
3 | 22.0 | cT3b | 7/10 | 4 + 5 | 2.8 | pT2a | 4/12 | 10 | 4 + 5 | Negative | Triptorelin |
4 | 61.0 | cT3a | 12/12 | 4 + 5 | 4.0 | pT3b | 12/12 | 75 | 5 + 4 | Positive | Triptorelin |
5 | 7.8 | cT3a | 7/7 | 4 + 4 | 3.9 | pT2c | 12/12 | 40 | 4 + 3 | Positive | Triptorelin |